Showing results (51-60 of 96) with videos related to
Sort By:
Pageof 10
Journal of Gastrointestinal Oncology|May 22, 2026
Assessment of colorectal cancer recurrence risk following solid organ transplantationDavid B Meyer, Angela Gifford, Taylor Bradley, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|January 18, 2015
What is the Significance of Indeterminate Pulmonary Nodules in Patients Undergoing Resection for Pancreatic Adenocarcinoma?Katherine E Poruk, Yuhree Kim, John L Cameron, et al.Annals of Surgical Oncology|April 29, 2014
The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinomaWenchuan Wu, Jin He, John L Cameron, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|September 23, 2018
Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant ChemotherapyAmmar A Javed, Michael J Wright, Ayat Siddique, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2008
Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumorsAntonio Jimeno, Michelle A Rudek, Peter Kulesza, et al.Cancer Biology & Medicine|February 25, 2021
Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cellsArsen Osipov, Alex B Blair, Juliane Liberto, et al.Oncotarget|September 16, 2015
Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patternsTamna Wangjam, Zhe Zhang, Xian Chong Zhou, et al.Investigational New Drugs|December 14, 2011
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignanciesGlen J Weiss, Manuel Hidalgo, Mitesh J Borad, et al.Frontiers in Immunology|March 25, 2026
Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinomaArielle Urman, Yingjun Ding, Jennifer Durham, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|February 5, 2026
Post-surgical ctDNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinomaMatthew Z Guo, Apoorvaa S Sachidanand, Thanh Nguyen, et al.Pageof 10